Sigmanomics
Back to all insights

Unlocking the Future of Drug Development: Serina Therapeutics to Speak at Prestigious LNP Immunogenicity & Toxicity Summit

Unlocking the Future of Drug Development: Serina Therapeutics to Speak at Prestigious LNP Immunogenicity & Toxicity Summit

HUNTSVILLE, AL, Dec. 11, 2024 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, announced that Serina Therapeutics’ Chief Development Officer, Randall Moreadith, MD, PhD, will be presenting today at the 3rd Annual LNP Immunogenicity & Toxicity Summit in Boston, MA.

Breaking Boundaries in Drug Development

Serina Therapeutics is at the forefront of revolutionizing drug delivery technology with its innovative POZ Platform™. The company’s Chief Development Officer, Randall Moreadith, MD, PhD, is set to share groundbreaking insights at the prestigious LNP Immunogenicity & Toxicity Summit.

The presentation titled “Overcoming Anti-PEG Antibody Responses – A Novel PEOZ-lipid That Fails to Elicit an Immune Response to the Polymer-lipid in mRNA-LNP Formulations” promises to unveil a new era in drug development. Serina Therapeutics’ cutting-edge approach addresses the challenge of immune responses to polymer-lipid formulations, paving the way for enhanced efficacy and safety in mRNA-LNP formulations.

By leveraging the unique properties of the POZ Platform™, Serina Therapeutics is poised to overcome obstacles that have hindered traditional drug delivery methods. The company’s commitment to innovation and research excellence positions it as a key player in shaping the future of pharmaceuticals.

Impact on Individuals:

For individuals, the advancements presented by Serina Therapeutics hold the promise of more effective and safer drug treatments. By minimizing immune responses to drug formulations, patients may experience reduced side effects and improved treatment outcomes. This could lead to a higher quality of life for those suffering from various medical conditions.

Global Implications:

The innovations showcased by Serina Therapeutics at the LNP Immunogenicity & Toxicity Summit have the potential to revolutionize the pharmaceutical industry on a global scale. By addressing challenges related to immunogenicity and toxicity in drug development, these advancements could lead to the creation of more targeted and efficient therapies. This could ultimately benefit populations worldwide by providing access to improved pharmaceutical solutions.

Conclusion:

With its groundbreaking presentation at the LNP Immunogenicity & Toxicity Summit, Serina Therapeutics is not only unlocking the future of drug development but also setting new standards for innovation in the biotechnology sector. The company’s dedication to overcoming challenges and pushing boundaries highlights its commitment to improving the lives of individuals and transforming the landscape of healthcare worldwide.

more insights

“Navigating the Storm: Ethereum’s Struggle with Leadership and Market Demand”

January 24, 2025

Ethereum’s Uncertain Path Forward Challenges Facing the Ethereum Foundation Ethereum’s path forward is becoming increasingly uncertain, with growing calls for leadership reform to address significant governance challenges. The Ethereum Foundation, the organization responsible for overseeing the development of the Ethereum platform, is facing internal pressure and external market shifts that

Read more >
Sigmanomics

Menu

About

News

Signals

Risk Disclaimer: Sigmanomics is a financial portal that provides news and analysis about the different financial markets. The articles that we serve on the portal depend solely on the opinion and analysis of our economists which in no way are intended to incite a visitor of the website or an investor to trade or sell/buy a certain instrument. It is the responsibility of the visitor / trader only to evaluate his trading strategies and whether he is capable of trading with taking into consideration that losing all the capital invested is a possibility. The visitor should seek an independent professional financial advisor to discuss his or her trading strategies. Moreover, the provided rates for the different instruments are indicative only and cannot be used for trading purposes. Therefore, no responsibility can be imposed on sigmanomics.com.com and the company operating the portal for any loss of money that may occur to the visitor by using the website.